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A B S T R A C T   
The advancement of artificial intelligence concurrent with the development of medical imaging techniques 
provided a unique opportunity to turn medical imaging from mostly qualitative, to further quantitative and 
mineable data that can be explored for the development of clinical decision support systems (cDSS). Radiomics, a 
method for the high throughput extraction of hand-crafted features from medical images, and deep learning -the 
data driven modeling techniques based on the principles of simplified brain neuron interactions, are the most 
researched quantitative imaging techniques. Many studies reported on the potential of such techniques in the 
context of cDSS. Such techniques could be highly appealing due to the reuse of existing data, automation of 
clinical workflows, minimal invasiveness, three-dimensional volumetric characterization, and the promise of 
high accuracy and reproducibility of results and cost-effectiveness. Nevertheless, there are several challenges that 
quantitative imaging techniques face, and need to be addressed before the translation to clinical use. These 
challenges include, but are not limited to, the explainability of the models, the reproducibility of the quantitative 
imaging features, and their sensitivity to variations in image acquisition and reconstruction parameters. In this 
narrative review, we report on the status of quantitative medical image analysis using radiomics and deep 
learning, the challenges the field is facing, propose a framework for robust radiomics analysis, and discuss future 
prospects.   
1. Introduction 
Advances in artificial intelligence applications, combined with those 
in medical imaging, have led to the gradual conversion of digital med-
ical images into high-dimensional data appropriate for data mining and 
data science techniques [1]. Meanwhile, computing power and quanti-
tative image analysis (QIA) techniques have made enormous progress, 
and the application of quantitative imaging techniques on medical im-
aging gained exponential momentum [2]. Currently, radiomics and deep 
learning are the most researched techniques on medical imaging. 
Broadly, radiomics refers to the use of computational or statistical 
approaches to extract large numbers of quantitative features from a 
number of medical imaging modalities, such as computed tomography 
(CT), magnetic resonance imaging (MRI), and positron emission to-
mography (PET), to develop predictive models ultimately aiming to 
enable personalized clinical management [3–5]. Radiomic features are 
quantitative descriptions of the intensity, shape, volume, and texture of 
the region of interest (ROI), with the recent addition of more abstract 
features such as radial gradient and radial deviation [6]. Radiomics 
features are broadly divided into histogram-based and texture features. 
Different statistical methods are used to calculate the radiomics features. 
The methods include first-order statistics, which depends on the values 
of single voxels (histogram-based features for e.g. maximum and mini-
mum intensity); second-order statistics, which depends on the relation 
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between two voxels (for e.g. grey-level co-occurrence matrix (GLCM) 
features), and higher-order statistics (relations among three or more 
voxels, for e.g. neighborhood grey-tone difference matrices (NGTDM) 
features) [7,8]. The main hypothesis behind radiomics analysis is that 
radiomic features decode or correlate with the molecular characteristics, 
phenotype, and genotype of the region of interest (ROI) under study. 
This information can be used in combination with other patient infor-
mation to improve patient management. Moreover, as the tumors are of 
heterogeneous nature [9,10], clinical approaches, such as tissue bi-
opsies, might fail to characterize the entirety of the tumor [11]. In 
contrast, Radiomics takes the whole tumor region (or even the sur-
rounding or healthy tissue) into account, which enables a better char-
acterization [3]. Furthermore, frequent clinical imaging can transform 
radiomics into a non-invasive, easily repeatable, and cost-effective 
longitudinal approach for cDSS [12]. 
Deep learning (DL) is a field of data driven modelling techniques that 
utilizes the principles of simplified neuron interactions [13]. Using 
artificial neurons started to draw attention decades ago [14], but it only 
became a major research focus recently [15–17]. The artificial neuron 
model is used as a foundation unit to create complex chains of in-
teractions – DL layers. These layers are used to generate even more 
complex structures - DL architectures (see Fig. 1). The neural network 
(NN) training procedure is typically a cost-function minimization pro-
cess. The cost function measures the error of predictions based on the 
ground truth labels [18]. Due to the high complexity of the network 
architectures, computational limitations are reached when trying to 
solve the optimization task analytically. Henceforth, iterative algo-
rithms are used to overcome this issue. Commonly, these algorithms are 
variations of the gradient descent (GD). GD iteratively moves in the 
direction of steepest descent of the cost function, in order to find a local 
minimum. During the model training process, every image from the 
training dataset contributes to the cost minimization process. Thereby, a 
DL network learns how to solve a problem directly from existing data, 
and apply it to data it has never seen. These complex models contain the 
parameters (weights) for millions of neurons, which can be trained for 
the recognition of problem-related patterns in the data being analyzed. 
DL has been shown to be efficient in other fields, such as face recognition 
[19] and autonomous cars [20]. 
Since the introduction of the field, many studies have reported on the 
potential of such techniques for predicting patient outcomes [5,21,22]. 
The successful translation of QIA techniques into cDSS will have a sig-
nificant impact on the clinical workflow and current patient manage-
ment protocols. Clinicians will be able to non-invasively obtain a more 
detailed and accurate tumor characterization, in a shorter amount of 
time. Patients will have to go through less invasive procedures, while 
having treatment optimized based on their individual characteristics. 
Furthermore, patient-specific informed decisions can be made with 
more confidence. However, QIA is still developing in the field of medical 
imaging and several challenges, including the stability and reproduc-
ibility of imaging biomarkers, as well as the interpretability of the 
developed algorithms, need to be addressed before QIA can be translated 
to clinical applications. 
In this narrative review, we focus on the current status of the po-
tential of radiomics and deep learning to be incorporated in clinical 
decision support systems (cDSS), their challenges, as well as future 
prospects for these methods. We further propose a workflow to guide 
robust radiomics analysis. 
2. Quantitative image analysis for precision medicine 
The need for personalizing the management of patients has been 
widely reported [23,24]. QIA represents a suitable candidate to be 
incorporated into the body of personalized medicine due to the non- 
invasive three-dimensional characterization of the ROIs, the availabil-
ity of vast amounts of medical images, the longitudinal capabilities, and 
the cost-effectiveness of the method. 
The currently implemented imaging biomarker development work-
flow is generalizable across different imaging modalities. The workflow 
can be described as consecutive steps divided into the main categories of 
data collection, image segmentation, features extraction, development 
of the signature, and evaluation of the performance (Fig. 2), with the 
segmentation step being optional in the case of deep learning. The 
workflow has been previously extensively described [22,25]. 
Many studies have investigated and reported on the added clinical 
value of radiomics features for predicting various clinical outcomes, 
such as overall survival, tumor histology, response to therapy, and ge-
netic profiling, among other endpoints. Furthermore, these studies were 
performed on various imaging modalities, including CT, MR, and PET. 
While the hand-crafted radiomics pipeline necessitates the use of 
machine learning or statistical algorithms after feature extraction for 
modeling, DL techniques perform feature extraction and modelling 
internally without the need for further user interaction. DL has its own 
advantages and drawbacks compared to traditional radiomics. One of 
the key benefits of using DL is avoiding the contouring problem, the 
bottleneck of a traditional radiomics pipeline. However, due to the 
complexity of DL models, it is easier to overfit the model to the training 
data. As a result, a larger data set is needed for DL compared to hand- 
crafted radiomics. Furthermore, DL is considered a ‘black box’, i.e the 
models and features generated are not (or barely) interpretable. This is 
currently one of the major challenges of the application of artificial in-
telligence (AI) in medical image analysis. Efforts are being made to-
wards providing explainable AI algorithms, by investigating the 
correlation of the chosen features with biologic or semantic character-
istics. Such correlations would provide an understanding about how the 
algorithm makes the decision, and ease its incorporation into cDSS. 
QIA techniques have a great potential for involvement in developing 
classification, prognostic and predictive clinical tools. In comparison, 
classification tasks (for e.g classifying tissue histology) seem to yield a 
better performance than predictive tasks (for e.g survival prediction). 
This is in part due to the unaccounted for variables when trying to 
predict future events. In 2.1 and 2.2, we report on some examples that 
highlighted the potential of radiomics and deep learning to predict 
various clinical endpoints, acknowledged or addressed the challenges of 
QIA techniques used, and/or applied the techniques on a relatively large 
sample size compared to other studies addressing the same clinical 
endpoint. 
Fig. 1. Graphical depiction of DL architectures. * FCN: fully connected network.  
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2.1. Hand-crafted radiomics 
2.1.1. Overall survival 
Wang et al. [26] investigated the potential of radiomics signatures to 
predict overall survival in patients with locally advanced rectal cancer. 
The authors tried to address the current clinical need for a risk stratifi-
cation tool for such patients to safely forgo surgical resection, due to the 
high comorbidities associated. The study included 411 treatment plan-
ning CT-scans of patients treated with neoadjuvant chemotherapy fol-
lowed by surgery. The authors developed a radiomics signature that 
could stratify patients into low- and high-risk survival groups. The 
radiomic features included in the signature were found to be indepen-
dent of the clinical features. Adding radiomic features to the clinical 
model resulted in an improvement of the predictive power (c-index) of 
the clinical only model from 0.67 (0.62–0.73) to 0.73 (0.66–0.80) [26]. 
The authors used two investigations to ensure the selection of stable 
radiomics features, namely test–retest and contour-recontour robustness 
analysis. The results signifies the added value of properly using radio-
mics analysis on CT scans in improving patients’ risk stratification. Yet, 
the authors did not externally validate their signature, casting doubt on 
the generalizability of their signature. It is expected to be of value in 
cases where the scanning parameters are identical to those used in the 
study. 
Another study by Bae et al. [27] investigated the potential of MR- 
based radiomics to improve the survival prediction of patients diag-
nosed with glioblastoma multiforme. The study is an effort to address 
the unmet clinical need for assessing the survival of the target group 
following therapy. The authors extracted radiomics features from 217 
multiparametric MR scans of patients with glioblastoma. The authors 
identified 18 radiomics features to build a radiomic signature, and re-
ported that the addition of radiomics features to clinical and genetic 
profiles of the patients significantly improves the stratification of pa-
tients [27]. The authors in this study applied a unique approach for the 
analysis by simultaneously analyzing radiomics features extracted from 
different co-registered MR sequences. The identified features were in-
dependent of the clinical and genetic factors, and the improvement in 
the survival prediction following their addition, supports the hypothesis 
of radiomics. Pitfalls in the study include the lack of assessment of 
radiomic feature stability before modeling, and as often seen in these 
studies, a lack of an external validation of the signature. However, their 
results support the hypothesis that radiomics are of great use when 
applied on scans acquired using identical settings. 
Oikonomou et al. [28] reported on the potential of PET/CT-based 
radiomics to improve the survival stratification of patients with lung 
cancer treated with stereotactic body radiotherapy. The aim was to 
identify radiomic features that can improve the prognostication of pa-
tients following treatment. The authors extracted radiomics features 
from 150 PET/CT scans, and built radiomics signatures using 10 
radiomics features. The authors reported that the radiomics signature 
was the sole predictor in the case of overall survival, and provided 
complementary information for the prediction of regional control [28]. 
The uniqueness in this study is the joint use of radiomics features 
extracted from the CT-component and PET-component of the PET/CT 
scans. The authors show how other currently used clinical parameters 
fail to predict overall survival, while only radiomics could. While the 
study highlights the potential of radiomics to improve risk stratification, 
no external validation of the signature was performed. 
2.1.2. Progression free survival 
Kirienko et al. [29] investigated the role of PET/CT-based radiomics 
to predict disease free survival in patients with non-small cell lung 
cancer undergoing surgery. The authors extracted radiomics features 
from PET, CT, and combined PET/CT images. The authors developed 
Cox regression models using only CT, only PET, and combined PET/CT 
radiomics features. They reported that the radiomic signatures they 
developed improve the current clinical stratification of the targeted 
patients [29]. The authors in this study investigated the reproducibility 
of radiomics features across the different imaging parameters in their 
dataset. This ensured selecting the comparable features before pro-
ceeding with signature building. The authors also provide evidence of 
the added value of combining radiomics features extracted from 
different imaging modalities. Furthermore, the ability to predict disease 
free survival from the time of diagnosis -which radiomics offer- im-
proves physicians and patients decision making. However, the authors 
in this study did also not perform an external validation of their signa-
ture. Further validation of the signature can prompt a prospective 
validation trial, before incorporation into cDSS. 
Another study by Kickingereder et al. [30] investigated the role of 
MR-based radiomics in predicting survival in patients with glioblastoma 
multiforme. The authors extracted radiomics features from 119 MR 
scans, and developed a radiomic signature using 11 features. The 
developed signature performed significantly better than the radiologic 
Fig. 2. Development of imaging biomarkers using quantitative image analysis. * Segmentation is not a necessity in the automated radiomics pipeline.  
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and clinical risk models, and its addition to those resulted in an overall 
improvement of progression-free survival stratification [30]. The 
finding that the radiomics signature performed better than the clinical 
and radiologic models supports the findings reported by Bae at al. [27], 
and adds more evidence that radiomic features decode complementary 
biologic information. However, the study did not address the issues of 
the reproducibility and generalizability sufficiently, leaving a room for 
improving the performance of radiomics. 
2.1.3. Tumor histology 
Wu et al. [31] explored the role of radiomics in differentiating be-
tween the histologic subtypes of non-small cell lung cancer: adenocar-
cinoma and squamous cell carcinoma. The study was an effort to address 
the clinical need for less invasive and easily repeatable methods to 
determine tumor histology. The authors extracted radiomic features 
from 350 CT scans of NSCLC patients for whom the tumor histology has 
been determined from surgical specimens. The developed signature 
included 5 radiomics features, and they reported an area under the 
receiver characteristics curve (AUC) of 0.72 [31]. This study reflected on 
the potential of non-invasive radiomic signatures to differentiate be-
tween adenocarcinoma and squamous cell carcinoma. They also inves-
tigated different machine learning methodologies for building the 
radiomics signature. While this study generates evidence for the po-
tential of radiomics, the performance of the developed signature is 
significantly lower than the current gold standard -tissue biopsy. How-
ever, there is a great room for improving the development and perfor-
mance of the signature. The authors did not address the acknowledged 
challenges in radiomics, nor did they validate their signature on an 
external dataset. Preselection of reproducible features, external and 
prospective validation of the signature are necessary steps in the 
development of radiomics biomarkers. 
In another study, Wu et al. [32] investigated the added value of MR- 
based radiomic features for the prediction of hepatocellular carcinoma 
(HCC) grade. The authors extracted radiomic features from 170 MRI 
scans of HCC patients, whose tumor grade was identified through 
pathological samples. The radiomics-only signature (AUC of 0.74) out-
performed the clinical model (AUC of 0.60), and the combination of 
both significantly improved the prediction (AUC of 0.80) [32]. The 
authors in this study also combined radiomic features extracted from 
two different MR sequences and analyzed them simultaneously. The 
significant improvement of the predictions following the combination of 
clinical and radiomic features supports the independence of radiomics 
features from other clinical information. However, external validation of 
the developed signature is still a necessity before confidently performing 
prospective validation. 
Valleries et al. [33] explored the potential of the combination of 
FDG-PET- and MR- based radiomics features to classify lung nodules. 
The authors extracted radiomics features from 51 PET and MR scans of 
histologically confirmed lung lesions in patients with soft-tissue sar-
coma. The authors achieved a sensitivity of 0.96 and specificity of 0.93 
in diagnosing metastatic nodules using a model with combined radiomic 
features from both PET and MR modalities. The authors used a novel 
interesting approach by simultaneously analyzing the features extracted 
from FDG-PET and MR scans, and were the first to show the potential of 
this method. The performance of the developed signature makes it a 
suitable alternative for patients for whom tissue biopsy is contra-
indicated. Its possible translation to cDSS might significantly improve 
patient outcomes, as treatment is based on the histologic diagnosis. Yet, 
further external and prospective validation of the signature is needed. 
2.1.4. Response to therapy 
Trebeschi et al. [34] explored the role of radiomics in predicting 
response to anti-PD1 immunotherapy in patients diagnosed with 
advanced melanoma and NSCLC patients. Immunotherapy has shown 
promising results. Yet, there is still a need for a tool to determine which 
patients will benefit from receiving anti-PD-1 antibodies. The authors 
extracted radiomic features from 1055 ROIs segmented on 203 CT scans. 
The authors developed a radiomic signature that could predict the 
response to therapy with an AUC of 0.76; showing the potential of 
radiomics to predict response to therapy in such patients [34]. Inter-
estingly, the authors found correlations between the radiomic biomarker 
and the genes associated with cell cycle progression and mitosis. 
Radiomics can become a tool for assisting decision making in immu-
notherapy, a great unmet clinical need. The study however did not 
externally validate the signature, and did not sufficiently address the 
issues of feature stability and reproducibility. Therefore, the application 
of the developed signature is also limited to the patients who are scan-
ned with the same scanning parameters as used in the training. 
In a study by Horvat et al. [35], the authors investigated the role of 
radiomics in assessing complete clinical response (cCR) after neo-
adjuvant chemoradiotherapy (CRT) in patients with locally advanced 
rectal cancer. The guidelines of treating these patients include surgery, 
but evidence showed recently that a select group of patients can be 
safely treated with only CRT. The authors extracted radiomic features 
from 114 MR scans, and developed a radiomics signature with a sensi-
tivity of 1.00, and a specificity of 0.91, which outperformed qualitative 
assessment of the response performed by two radiologists. The current 
clinical standard evaluation of cCR includes digital rectal examination 
and endoscopy, with an accuracy ranging between 0.71 and 0.88 [35]. 
The developed radiomic signature showed the highest accuracy among 
the available compared-with tools. Nonetheless, several steps to 
improve the methodology and performance of the radiomics signature 
could be made. The sound cCR evaluation following RCT can improve 
the patient management by eliminating surgical risks, time and money. 
2.2. Deep learning 
The application of deep learning on medical imaging could poten-
tially fulfil more complicated tasks than hand-crafted radiomics, espe-
cially when large amounts of data are available. Furthermore, as 
definition of the ROIs is not a necessity in the automated deep learning 
workflows, the algorithm will learn patterns from the whole image and 
possibly make connections with the habitat of the ROIs. The applications 
of neural networks on medical imaging are also not limited to classifi-
cation and prediction of clinical end points, but can extend to include 
other tasks, such as the detection and segmentation of abnormalities or 
target volumes, which have been investigated for decades [36]. Espe-
cially the detection and segmentation of lesions can be easily incorpo-
rated into the radiomics workflow, further automating the process. In 
the following paragraphs, we give examples of different applications of 
DL on medical imaging to perform various tasks on datasets acquired 
with one of the three main medical images modalities: CT, MRI, and 
PET. 
2.2.1. Automatic segmentation of target structures 
Jiang et al. [37] tried to develop a DL model that is able to accurately 
perform volumetric lung tumor segmentation on CT images. The authors 
used two versions of multiple resolution residual network models for the 
delineation of the ROIs. The authors used 377 tumors from the open 
source dataset available on The Cancer Imaging Archive (TCIA) 
(https://www.cancerimagingarchive.net) to train the model, and two 
independent datasets of 304 and 529 lung tumors to validate it. The dice 
similarity coefficient (DSC), which measures the spatial overlap of the 
segmentations, was computed to evaluate the performance of the model. 
The DSCs of the model on the two validation datasets were 0.75 and 
0.68, respectively. The authors reported that there was no significant 
difference between the DL-generated mask and experts’ segmentations 
[37]. The new approach for segmenting medical images used in this 
study shows to be superior to the traditional use of UNet. The approach 
generalizes well on external data and overcomes the multiple sizes 
problem. The major pitfalls is that the authors did not use the 3D ge-
ometry of the CTs to compute the results, which would probably 
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increase the performance significantly. The translation of such a tool to 
clinical practice will significantly reduce the time spent by the clinicians 
to plan the treatment, or evaluate the response to therapy. Moreover, 
from a research perspective, it can significantly reduce the time needed 
for radiomics research, and it will address the issue of inter-observer 
sensitivity of radiomics features. 
In the study by Yi et al. [38], the authors developed a DL model for 
the segmentation of brain tumors based on 274 brain MRIs extracted 
from the Brain Tumor Image Segmentation Benchmark (BRATS) dataset 
[39]. Segmentation of brain Glioblastoma on MRI is a time-exhaustive 
process, and an automated, accurate and reproducible tool for this 
purpose is considered a clinical need. The model was trained using four 
different MRIs sequences. The particularity of their convolutional neural 
network (CNN) model is a fixed difference of Gaussian filters as a first 
convolution layer, as it was proven to be the most efficient for 3D seg-
mentation. The DSC for the model was 0.89 on the BRATS dataset when 
compared to ground truth segmentations [38]. This article shows the 
superiority of 3D CNN compared to 2D CNN. The algorithm generated 
segmentations with a volumetric overlap of 0.89 with the experts’ seg-
mentations, which shows the potential of these tools for clinical use. 
However, the lack of external validation in the study limits the appli-
cability of the algorithm to scanning parameters in the training set. The 
clinical practice can benefit from such tools, as it significantly reduces 
the time the clinicians spend, and can provide more accurate evaluation 
of tumor response than the current clinical routine. 
Chen et al. [40] explored the possibility of developing a DL model 
that is able to detect and segment cervical tumors on PET imaging. The 
authors proposed prior information constraint CNN (PIC-CNN), which 
integrates a CNN with prior information of cervical tumor. The authors 
reported a DSC of 0.84, which was superior to the other methods tin the 
comparison, including transfer learning based on fully convolutional 
neural networks (FCN) (DSC of 0.77), automatic thresholding (DSC of 
0.59), and region growing method (DSC of 0.52) [40]. The study high-
lights the potential of deep learning to perform well-defined and robust 
segmentations on PET imaging. The novelty of the approach is the use of 
prior information as input of the model, with delineation of the bladder. 
This extra information seems to give the traditional model an advantage 
compared to models that solely segment the tumors. However, the re-
sults were not validated on an external dataset. The application of the 
developed algorithm -after validating it- would decrease the need for 
tissue biopsy, as well as the time spent on segmenting the tumors 
manually or semi-automatically. 
2.2.2. Oncologic classification tasks 
Ardila et al. [41] tried to predict the risk of lung cancer using 
screening low-dose CTs. The algorithm is trained on screening low-dose 
CT scans of patients who were known to be at risk. The authors trained 
their DL model on approximately 7000 scans, and validated its perfor-
mance on 1139 cases. The authors reported that the model achieved the 
“state-of-the-art” performance (AUC of 0.944). Furthermore, the model 
outperformed all the radiologists (n = 6) who were asked to give pre-
dictions. The model resulted in a significant reduction in the false pos-
itive (11%), and false negative rates (5%) [41]. While the current low- 
dose CT screening protocol has substantially improved in terms of 
consistency, it still faces major limitations represented in the inter- 
observer variability and incomplete characterization of image find-
ings. The authors in [41] developed an algorithm that achieved signif-
icantly better performance than the current protocol, highlighting the 
potential of DL algorithms to revolutionize the field of lung cancer 
screening. Other advantages of the algorithm are that it eliminates the 
current clinical practice limitations. 
Ismael et al. [42] investigated the ability of DL algorithms to classify 
different brain tumors. The algorithm predicts if the lesion is one of: 
Meningiomas, Gliomas, and Pituitary tumors. The authors developed the 
algorithm on 3064 T1 MRI images from 233 cancer patients. As input to 
the algorithm, the 2D images were considered independent from each 
other, and were split into 80% training and 20% testing, with strictly 
different patient data. The classifier used is ResNet50, a classic deep 
learning network, and the resultant balanced accuracy was 0.99 on a 
slice level and 0.97 at a patient level. This study shows that deep 
learning can very accurately classify brain tumors based solely on MRI 
data. However, the data to be used should be acquired using the same 
scanning parameters, as no external validation was performed in this 
study. There is a great clinical significance from the development of such 
a cDSS, as it eliminates the need for risky brain biopsies, while main-
taining high accuracy. 
In another study by Sibille et al. [43], the authors used the combi-
nation of CT, fluorine 18-fluorodeoxyglucose PET, atlas and PET 
maximum intensity projection (MIP) imaging to classify lung nodules. 
The study included a set of 629 patients who were diagnosed with either 
lung cancer or lymphoma. The authors developed models using each of 
imaging modalities separately, as well as in combination. The recom-
mended algorithm achieved an AUC of 0.98 when both CT and PET were 
combined [43]. This study shows that the combination of CT and PET 
can achieve an outstanding performance in terms of predictions. The 
current clinical practice requires the clinician to review and classify all 
of the increased-uptake foci in a PET/CT scan. The algorithm could help 
the clinicians to quickly read those images, after highlighting the sus-
picious areas and their most likely classification using DL. 
2.2.3. Non-oncologic classification tasks 
Walsh et al. [44] explored the potential of DL to classify fibrotic lung 
diseases using high resolution CT scans. The current clinical guidelines 
for classifying fibrotic lung diseases are based on high resolution scans, 
and diagnoses are made based on the semantic features identified by the 
radiologists. While these guidelines are the current gold-standard, it 
suffers greatly from inter-observer variability. The authors tried to 
address this unmet clinical need using DL approaches. The authors 
trained their DL model on 929 CT scans, and tested it on 139 scans. The 
authors reported a performance with human-level accuracy (0.76) [44]. 
Of interest, the algorithm developed had a better agreement with expert 
radiologists than among them. The ease of application of such methods 
in clinical settings could benefit clinical practice, especially in centers 
where such clinical expertise is scarce. 
In the study by Ding et al. [45], the authors tried to develop a DL 
model that is able to diagnose Alzheimer’s disease (AD), using 18F-FDG 
PET scans of the brain. The current clinical guidelines to diagnose AD 
necessitate the interpretation of scans by an expert, and there is no 
definitive biomarker. To investigate the potential of DL, the authors 
collected two datasets: one used for training and testing the model (n =
2109 scans), which was split into 90% training and 10% testing; and an 
independent dataset (n = 40) for the validation of the model. The au-
thors reported an AUC of 0.98, sensitivity of 1.00 and specificity of 0.82, 
using scans acquired 75.8 months on average before establishing the 
diagnosis. The model further outperformed the readers’ performance 
(sensitivity of 0.57 and specificity of 0.91) [45]. The significance in this 
study lies within the novelty of developing a biomarker for AD that is 
currently an unmet clinical need. In addition to the significantly better 
performance compared to human experts, the model can predict that the 
patient has AD in progression significantly earlier (~6 years). Such an 
application will revolutionize the clinical management of AD. However, 
prospective validation of this signature is needed before its translation to 
clinical practice. 
Oh et al. [46] applied a DL based approach in order to classify the 
neuroimaging data related to AD. Authors used 694 MRI scans (T1- 
weighted MP-RAGE sequence) for solving several binary classification 
problems: AD vs. normal control (NC), progressive mild cognitive 
impairment (pMCI) vs. NC, stable mild cognitive impairment (sMCI) vs. 
NC and pMCI vs. sMCI. The authors utilized convolutional autoencoder- 
based unsupervised learning algorithms in order to classify the AD vs. 
NC. Following that, the authors applied a supervised transfer learning 
approach to classify the pMCI vs. sMCI. The developed algorithms 
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achieved accuracies of 0.87, 0.77, 0.63, and 0.73 for the AD, pMCI, sMCI 
and pMCI vs. sMCI classifications, respectively. In comparison to Ding 
et al. [45], the authors in this study used different DL approaches, and 
less numbers of patients were available for training and testing the al-
gorithm. Furthermore, the difference in the imaging modality analysed 
in each study could justify the variation in performance, as AD begins 
with functional impairment rather than structural changes. Although 
the model developed by oh et al. [46] was outperformed by human 
experts, the authors demonstrated the possibility of end-to-end DL al-
gorithms, which could be translated to clinical use after further opti-
mization and prospective validation. 
2.2.4. Response to therapy 
Lou et al. [47] reported on the potential of DL models to predict 
response to radiotherapy in patients with lung cancer (primary or met-
astatic) using CT scans. Currently, all patients are treated similarly, 
while personalizing radiotherapy remains a desired, but unmet clinical 
need. The authors in this study collected a total of 849 scans for training 
the DL algorithm, and 95 scans to validate it. The authors developed a 
deep learning model (deep profiler) that computes and includes radio-
mic features in the deep-profiling process. A model combining the deep 
profiler and clinical variables is then used to calculate a risk score that is 
used to predict the response to treatment. The algorithm classifies pa-
tients into high and low risk groups, with a high performance (c-index of 
0.72), which is significantly better compared to the results obtained with 
solely handcrafted radiomic models (c-index between 0.65 and 0.68) 
[47]. The algorithm developed in this study opens new potentials for 
individualizing radiotherapy based on patients’ sensitivity. Thereby, 
avoiding over- or under-treatment, and the side-effects of unnecessary 
treatment. Nevertheless, proper prospective validation of the developed 
algorithm remains a necessity. 
Ypsilantis et al. [48] used convolutional neural networks to develop 
a model that is capable of predicting response to neo-adjuvant chemo-
therapy (NAC) in patients with esophageal cancer using PET scans. NAC 
is considered a standard of care in some cancers. While NAC has 
favourable outcomes in patients who respond, patients who do not end 
up with worse outcomes. To investigate the potential of QIA techniques, 
the authors collected 107 PET scans of patients diagnosed with esoph-
ageal cancer, treated with NAC, and followed-up to determine response. 
The authors compared the performance of hand-crafted radiomics with 
deep learning approaches. The authors reported that the developed deep 
learning algorithm outperformed the hand-crafted radiomics model, and 
achieved a sensitivity of 0.81 and specificity of 0.82 [48]. The algorithm 
developed in this study highlights the potential of using DL to predict 
patients’ response to therapy at baseline, which is considered a sub-
stantial clinical added value. 
3. Challenges and future directions 
Biomarkers are defined as “objective indications of medical state 
observed from outside the patient – which can be measured accurately 
and reproducibly” [49]. The core of choosing a biomarker is the ability 
to measure it objectively. The reproducibility of imaging quantitative 
features across different imaging parameters is currently the steepest 
hurdle in QIA. As more research is being performed, other challenges, 
such as the sensitivity of QIA features to variations in the segmentation 
of the ROIs; and the lack of feature reproducibility across different 
implementations of radiomics toolboxes, are becoming increasingly 
clear. 
3.1. The stability and reproducibility of quantitative features 
Since the first landmark study in radiomics by Aerts et al. [50], the 
sensitivity of radiomic features to repeated acquisitions has been 
acknowledged. The authors performed a test-retest stability investiga-
tion, and used 100 out of 440 calculated radiomic features based on the 
stability rank of the features. The authors also acknowledged the 
sensitivity of features to differences in segmentations, and performed a 
primary feature selection based on the features’ robustness with regards 
to differences in both test-retest and segmentations. More recently, 
several studies reported on the sensitivity of radiomic features to tem-
poral changes in test-retest studies across different modalities, including 
CT, MRI, and PET. 
3.1.1. Anatomical imaging 
Anatomical imaging (CT and MRI) is used to explore the underlying 
anatomical structures. CT imaging is standardized using the hounsfield 
units (HU) [51]. On the other hand, MR imaging has no such stan-
dardized intensity measurements [52]. Even though CT imaging uses 
standardized measurements, CT-based radiomics are not necessarily 
reproducible. Several studies reported that a significant number of CT- 
based radiomic features are not reproducible in test-retest settings, 
where the scans are acquired using the same scanning parameters 
[53–55]. Other studies that investigated the reproducibility of CT-based 
radiomics features across different imaging acquisition and reconstruc-
tion parameters reported that the majority of radiomic features are 
significantly affected by such differences [53,56,57]. Unreproducible 
radiomic features should be removed before starting the modeling of 
radiomics signatures. Therefore, it is always necessary to perform pre-
selection of stable radiomics features based on the data under study, 
before starting the modeling. 
MR-based radiomics is even more complex and challenging to stan-
dardize compared to CT based radiomics, as more factors -in addition to 
lack of standardized intensity measurements- affect MR imaging [58]. 
Some studies reported on the stability of various MR-based features. 
Fiset et al. [59] investigated the reproducibility of T2-weighted MRI of 
cervical cancer in three different settings: (i) test–retest; (ii) diagnostic 
MRI versus simulation MRI; (iii) interobserver variability. The authors 
reported that 22.6%, 6.2% and 74.4% of 1761 extracted radiomics 
features were reproducible across test-retest, diagnostic versus simula-
tion MRI, and different observers, respectively. Semi-parametric maps 
derived from specialized MRI sequences suffer less from the lack of 
stability: Peerlings et al. [60] reported on the stability of radiomics 
features extracted from apparent diffusion coefficient (ADC) map in test- 
retest and across different cancer types, centers, and vendors. The au-
thors reported that out of 1322 extracted radiomics features, 122 fea-
tures were stable across all cancers, centers, and vendors. 
On top of these challenges, using contrast agents for imaging adds 
another level of complexity to the reproducibility of features, due to the 
differences in the cardiac function of patients being scanned. Changes in 
cardiac function can affect the time the distribution of the contrast in the 
body takes [61]. Another factor in contrast-enhanced images is the 
difference in time between the injection of the contrast and scan 
acquisition, which might be slightly different across centers and 
protocols. 
3.1.2. Functional imaging 
Functional imaging is used to assess the metabolic activity of a region 
of interest, and includes the injection of radiopharmaceuticals. Some 
standardized measurements in PET are already being extracted and used 
in clinical practice, such as the standardized uptake value (SUV), and the 
metabolically active tumor volume (MTV) [7]. 
The challenges of radiomics for functional imaging are similar to the 
challenges of contrast-enhanced anatomical imaging radiomics, where 
the variability in the injected radiopharmaceutical activity, the time 
between injection and image acquisition, and acquisition time per bed 
position have profound implications on the reproducibility of radiomics 
features [62]. In addition, functional imaging lacks anatomical speci-
ficity and suffers from low resolution, which could be addressed by the 
use of hybrid imaging [22]. Tixier et al. [63] investigated the repro-
ducibility of SUV measurements, intensity histogram features, intensity- 
size zone features, and co-occurrence matrices features. The authors 
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acquired two 18F-FDG PET scans of 16 patients, with a 4-days’ time 
interval. In contrast to further studies, the authors reported that these 
features were insensitive to the discretization range. Hatt et al. [64] 
investigated the robustness of PET based heterogeneity textural features 
with respect to the delineation of functional volumes and partial volume 
effects correction. The authors reported that these features were 
significantly affected by the differences in the delineation. The authors 
further reported that local features, e.g entropy and heterogeneity, were 
more robust when compared to regional features, e.g intensity vari-
ability and size-zone variability. Leijenaar et al. [65] investigated the 
role of SUV discretization on radiomics features. The authors used two 
different methods for SUV discretization, and reported that differences 
in SUV discretization significantly affect the reproducibility of 18F-FDG 
PET based radiomic features. The authors recommended the standard-
ization of methodology for radiomics analysis. Altazi et al. [66] inves-
tigated the reproducibility of PET based radiomic features in cervical 
cancer patients. The authors investigated the reproducibility in three 
different scenarios: (i) manual versus computer-aided segmentations, 
(ii) gray-level discretization, and (iii) reconstruction algorithms. The 
authors extracted 79 PET radiomics features, and reported that the 
percentage of stable features in the three scenarios were 13%, 5%, and 
1% respectively. Shiri et al. [67] explored the effects of different 
reconstruction on 18F-FDG PET radiomics. The authors studied the ef-
fects of several factors including number of sub-iterations, number of 
subsets, full width at half maximum (FWHM) of Gaussian filter, and scan 
time per bed position and matrix size. The authors reported that 47% of 
the features were found to be robust, and these include shape, 44% of 
the intensity based features, and 41% of the texture based features. 
However, with changes in matrix size, the authors reported that only 6% 
of the features were robust. 
The discrepancies in the reported percentages of stable/reproducible 
features across the reported studies are most likely linked to the varia-
tions between the datasets used in each of the studies in the scanners, 
and scans acquisition and reconstruction parameters combinations. 
However, these discrepancies are expected because of the different 
complexity of radiomics features, as well as the interaction between the 
different scanning parameters. All of the above mentioned studies re-
ported that a variable percentage of radiomics features are affected, 
which highlights the necessity of performing feature stability/repro-
ducibility studies based on the data under analysis before performing 
radiomics analysis. 
3.2. Sensitivity of quantitative imaging features to variations in the 
segmentation of the ROIs 
In QIA, the medical images are converted to numerical arrays before 
feature calculation. Consequently, it is intuitive that differences in seg-
mentations affect the quantitative imaging feature values variably, 
depending on the feature definition. Many studies have identified lists of 
radiomics features that are robust to variability in segmentations 
[50,68,69]. Furthermore, with the inclusion of deep learning methods in 
image analysis, efforts are being made to develop reliable and repro-
ducible automatic segmentations of various regions of interest as 
described in 3.2.1. Deep learning suffers less in this aspect, as the pro-
vision of ROIs is not obligatory. 
3.3. The different implementations of radiomics feature extraction 
toolboxes 
It is common knowledge in the radiomics community that different 
radiomics toolboxes use different pre-processing techniques and/or 
feature definitions, which lead(s) to variations in estimation of radio-
mics feature values when different software solutions are used. To 
address this issue, the radiomics community started an initiative – Im-
aging Biomarkers Standardization Initiative (IBSI) – that aims at stan-
dardizing radiomics feature extraction using different toolboxes [70]. To 
date, the IBSI standardized the extraction of 169 radiomics features 
[71]. Limiting the radiomics analysis to the IBSI standardized features 
can facilitate radiomic features interchangeability across platforms. 
3.4. Future directions 
To address the issue of radiomic features reproducibility, some 
harmonization methods have been investigated in the literature. Of the 
trending methods is Combine Batches (ComBat). ComBat is a statistical 
method that was developed to remove the batch effects in microarray 
expressions [72]. While several studies have reported on the application 
of ComBat harmonization in radiomics analysis as a means to remove 
batch effects [73,74], its direct application on radiomics data is not in 
concordance with the mathematical definition of ComBat [72], or with 
the hypothesis that radiomics correlate with biology. This is because 
ComBat assumes that the differences between batches are attributed to 
two groups of factors, the first group refers to the biological covariates, 
which radiomics features are investigated for correlations with. More-
over, adding biologic covariates for ComBat in the training of radiomics 
signatures will hinder its prospective use, because it will be the outcome 
the radiomic signature tries to predict. The second group refers to the 
“non-biologic” factors, such as image acquisition and reconstruction 
parameters. ComBat was defined to handle one batch effect at a time. In 
contrast to gene expression arrays for which ComBat was designed, 
radiomic features have different complexity levels, which are expected 
to be non-uniformly affected by the variations in imaging parameters. In 
addition, the differences in image acquisition and reconstruction set-
tings in a given retrospective imaging dataset are usually in more than 
one imaging parameter. The proper use of ComBat would require the 
assessment of the reproducibility of radiomics features after applying 
ComBat on representative objects with no biologic variations, such as 
phantoms. Then, radiomics features extracted from patients’ scans ac-
quired with the same imaging parameters can be transformed based on 
the location/scale parameters estimated by the application of ComBat 
on the phantom data. We here propose a framework for performing 
robust radiomics analysis (Fig. 3). Nonetheless, a radiomics-specific 
harmonization method is still needed to eliminate the need for phan-
tom studies, as the performance of ComBat is expected to be dependent 
on the variations in scanning parameters in the data. 
The workflow consists of consecutive steps, and can be used to pre-
select reproducible and harmonizable radiomics features. The first step 
in the workflow is the collection of retrospective patient imaging data to 
be analyzed. In the second step, scan acquisition and reconstruction 
parameters must be extracted from the collected patient data. The next 
step includes scanning a phantom with the parameters extracted from 
the patient imaging data. This allows the assessment of the reproduc-
ibility of radiomics features across the different scan acquisition and 
reconstruction parameters, and the selection of those features for per-
forming robust radiomics analysis. 
Based on our review of existing literature and our own experience, in 
order to use ComBat in the context of radiomics analysis (steps 5–7), two 
extra steps are needed. After selecting the features that are insensitive to 
the variations in the scanning parameters extracted from the patient 
data, features that are reproducible in test-retest in each of the combi-
nations of those scanning parameters must be identified. ComBat is then 
applied on the features that are reproducible in test-retest but not across 
different scanning parameters. The concordance of Radiomic features is 
assessed following the application of ComBat. The location/scale shift 
parameters estimated by performing ComBat on the phantom data are 
then applied to the radiomics features extracted from patient data to 
harmonize them. The combination of the identified stable and harmo-
nizable features can be further used to build the radiomics signature. 
The challenges discussed above raise questions about the future ap-
plications of radiomics, and the development of radiomic signatures as 
clinical biomarkers. To begin with, how to approach the concept of 
external validation in radiomics studies. Do radiomic signatures need to 
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be externally validated as is the case with other biomarkers, given all the 
challenges of reproducibility across different imaging settings? Or would 
the observatory prospective validation of a given signature in a specific 
image setting suffice? Does the development of radiomic signatures need 
to be specific for a scanner model and imaging settings? The ultimate 
solution will be the development of specific quantitative imaging pa-
rameters, as there is currently a clinical direction to personalize imaging 
settings per patient, which will have its toll on radiomics analysis. The 
direct application of radiomics analysis on data acquired heteroge-
neously could lead to spurious results, and inability of translating the 
results in a meaningful manner. 
4. Conclusion 
Quantitative imaging techniques (radiomics and deep learning) 
present a perfect candidate for personalizing patients’ management. 
Applying these techniques in a sound manner can provide highly ac-
curate and reproducible tools that minimize costs and time loss. How-
ever, to incorporate QIA in cDSS, the quantitative features should fulfil 
the definition of a biomarker, namely the stability and reproducibility. 
The future of quantitative image analysis in general lies within harmo-
nizing the imaging protocols across centers and scanners, or within the 
development of a unique global protocol for quantitative analysis scans. 
Hence, the development of radiomics-specific tools to harmonize med-
ical images and facilitate meaningful quantitative image analysis of the 
currently available retrospective data remains a necessity. Our proposed 
framework is expected to improve the robustness of radiomics analysis. 
Nevertheless, the benefits of the proper application and translation of 
QIA on medical imaging are undoubted. QIA techniques will be a 
valuable asset for both: the clinicians and patients. QIA can become an 
efficient means for aiding clinicians in risk stratification, early diagnosis, 
and improved management of patients. 
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